# 2026-08552: FDA Snubs Ozempic and Similar Drugs from Key Compounding List

2026-08552, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-05-01, effective Either electronic or written comments on the notice must be submitted by June 30, 2026.; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-08552
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-08552
- Title: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 23431
- Published: 2026-05-01
- Effective: Either electronic or written comments on the notice must be submitted by June 30, 2026.
- Comments close: 2026-06-30
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Snubs Ozempic and Similar Drugs from Key Compounding List

## Summary

The FDA is updating a special list of important drug ingredients that compounding pharmacies can use to make medicines. They decided not to add three popular drugs—semaglutide, tirzepatide, and liraglutide—to this list right now. People and companies have until June 30, 2026, to share their thoughts, which could affect future drug availability and costs.

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is evaluating substances that have been nominated for inclusion on a list of bulk drug substances (active pharmaceutical ingredients) for which there is a clinical need for outsourcing facilities to use in compounding (the 503B Bulks List). This notice identifies three bulk drug substances that FDA has considered and proposes not to include on the 503B Bulks List: semaglutide, tirzepatide, and liraglutide. Additional bulk drug substances nominated for inclusion on this list are under consideration and may be the subject of future notices.

## Effects PRIA read

- Three Drugs Not Added Now: cost, medium. The FDA proposes NOT to add semaglutide, tirzepatide, and liraglutide to the Section 503B Bulks List. That means outsourcing compounding facilities may not lawfully compound using those bulk drug substances unless the substance later appears on the 503B Bulks List or the drug product is on FDA's dr…
- Public Comment Deadline Set: mixed, low. FDA is accepting electronic or written comments on this notice through June 30, 2026. Stakeholders must submit comments by 11:59 p.m. Eastern Time on June 30, 2026 for them to be considered.
- What FDA Won't Count As 'Clinical Need': cost, medium. When deciding whether a bulk drug substance belongs on the 503B Bulks List, FDA says it will not treat supply issues (such as backorders), convenience of administration, or the cost of a compounded product versus an FDA-approved product as a basis for 'clinical need.'

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-08552 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal)
- [2026-08552 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-01/pdf/2026-08552.pdf)

## Related
- [Previous: 2026-08551, Florida Power and Light Company; St. Lucie Plant, Units 1 and 2; Subsequent Lic…](https://policyrisk.com/federal-register/2026-08551)
- [Next: 2026-08553, Supply Chain Gaps and Entrepreneur Assistance](https://policyrisk.com/federal-register/2026-08553)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-08552 (as of 2026-06-08).
